Gaviscon Dosing
For adults, take 2-4 chewable tablets four times daily after meals and at bedtime, not exceeding 16 tablets in 24 hours; for liquid formulation (Gaviscon Advance), take 10 mL four times daily. 1
Adult Dosing
The FDA-approved dosing for Gaviscon chewable tablets is straightforward:
- Standard dose: 2-4 tablets four times daily
- Timing: After meals and at bedtime, or as needed
- Administration: Must be chewed (DO NOT SWALLOW WHOLE), followed by half a glass of water or other liquid for best results 1
- Maximum daily dose: 16 tablets in 24 hours 1
- Duration limit: Do not use maximum dosage for more than 2 weeks 1
For the liquid alginate formulation (Gaviscon Advance), the dosing is 10 mL four times daily, which has been validated in multiple clinical trials for GERD management 2, 3, 4.
Pediatric Dosing
No FDA-approved pediatric dosing exists for Gaviscon. The drug label does not provide specific recommendations for children, and the available evidence focuses exclusively on adult populations. The product should be kept out of reach of children 1.
Renal Impairment Considerations
Gaviscon contains sodium and should be used with caution in patients on sodium-restricted diets 1. However, the FDA label does not provide specific dose adjustments for renal impairment.
Important Caveats:
- Drug interactions: Consult a physician or pharmacist before use if taking prescription medications, as antacids may interact with certain drugs 1
- Sodium content: The formulation contains sodium alginate; patients with renal impairment requiring sodium restriction should be particularly cautious
- Active ingredients: The formulation contains aluminum hydroxide (160 mg) and magnesium carbonate (105 mg) per dose 1, which can accumulate in severe renal impairment
Clinical Context:
While the evidence provided includes detailed renal dosing for other medications (gabapentin, oseltamivir, etc.), no such guidance exists for Gaviscon/alginate formulations. The mechanism of action—forming a physical barrier "raft" on gastric contents 5—suggests minimal systemic absorption, but the aluminum and magnesium components warrant caution in advanced renal disease.
In severe renal impairment (CrCl <30 mL/min), consider alternative GERD therapies due to potential accumulation of aluminum and magnesium, even though specific contraindications are not listed in the FDA label.